New cancer drug enters first human tests for advanced tumors
NCT ID NCT05646797
Summary
This early-stage study tested a new drug called ASP2074 in adults with advanced solid tumors that had spread or couldn't be removed by surgery. All participants had already tried all available standard treatments and were no longer benefiting from them. The main goals were to find a safe dose for future studies and check for side effects by giving different small groups of people increasing doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
-
Duke University
Durham, North Carolina, 27710, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
-
Next Oncology - Oncology
San Antonio, Texas, 78229, United States
-
Osaka International Cancer Institute
Osaka, Japan
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan
-
University of California Davis Health System
Sacramento, California, 95817, United States
-
University of Iowa Hospitals
Iowa City, Iowa, 52242, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.